A randomized clinical trial reveals effects of mindfulness and slow breathing on plasma amyloid beta levels

Nashiro, K., Cahn, B. R., Choi, P., Lee, H. R. J., Satchi, S., Min, J., Yoo, H. J., Mercer, N., Cho, C., Sordo, L., Head, E., Choupan, J., Mather, M.

University of Southern California · medrxiv

Paper

Abstract

Prior research suggests that meditation may slow brain aging and reduce the risk of Alzheimer's disease (AD). However, we lack research systematically examining what aspect(s) of meditation may drive such benefits. In particular, it is unknown how breathing patterns during meditation might influence health outcomes associated with AD. In this study, we examined whether two types of mindfulness meditation practice, one with slow breathing and one with normal breathing, differently affect plasma amyloid beta (A{beta}) relative to a no-intervention control group. One week of daily mindfulness practice with slow breathing decreased plasma A{beta} levels whereas one week of daily mindfulness practice with normal breathing increased plasma A{beta} levels. The no-intervention control group showed no changes in plasma A{beta} levels. Slow breathing appears to be a factor through which meditative practices can influence pathways relevant for AD.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The study claims that mindfulness meditation with slow breathing can decrease plasma amyloid beta levels, potentially influencing pathways relevant for Alzheimer's disease. This research is relevant as it explores a non-pharmacological intervention that may address mechanisms associated with brain aging and Alzheimer's disease, rather than merely treating symptoms.

Author of this paper? Send a correction.